1887

n Cardiovascular Journal of South Africa - VALUE study highlights the need for aggressive BP lowering in high-risk patients : drug trends in cardiology

USD

 

Abstract

Extracted from text ... 191 VALUE study highlights the need for aggressive BP lowering in high-risk patients Valsartan (Diovan(r)) achieves 23% reduction in new-onset diabetes and reduction in heart failure incidence and admissions in VALUE study The results of the VALUE (Valsartan Anti-hypertensive long-term use Evaluation) study, announced recently at the EHS (European Hypertension Society) Congress in Paris, will not only change the future of hypertension trials, 1 but will also add further impetus to the current emphasis on achieving target recommended BP control within a relatively short time, 2 according to the authors of the VALUE trial. The VALUE study of 15 ..

Loading

Article metrics loading...

/content/cardio/15/4/EJC23927
2004-07-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error